Skip to content

Pressure Support Ventilation With the Anesthetic Conserving Device

Respiratory Mechanical Effects of Sevoflurane Administered With the Anesthetic Conserving Device in Pressure Support Ventilation

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01017744
Enrollment
15
Registered
2009-11-23
Start date
2009-11-30
Completion date
2013-08-31
Last updated
2013-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intensive Care Ventilation

Keywords

Anesthetic Conserving Device, Anaconda®, Sevoflurane, Remifentanil, Sedation, Pressure support ventilation, Work of breathing, Intrinsic positive end expiratory pressure, Ventilatory dead space, Intensive care, Weaning of mechanical ventilation, Ventilated ICU patients in PSV, No more in acute state, No respiratory distress, Sedated by intravenous remifentanil, In light sedation as define by a Richmond Agitation Sedation Scale (RASS) of - 1 to - 2.

Brief summary

Sevoflurane inhalational anesthetic has got pulmonary effects such as bronchodilatation. These effects could be of interest in intensive care patients ventilated in pressure support ventilation mode. The purpose of this study is to evaluate mechanical respiratory effects of sevoflurane administered through a new specific heat and moister exchanger called the Anesthetic Conserving Device (AnaConDa®) in pressure support ventilation in intensive care patients. In fact, dead space and resistance generated by the device could cancel and even deteriorate the potential positive effects of sevoflurane on ventilation.

Detailed description

Pharmacological sedation is often necessary in mechanical ventilated intubated patient. Since a little time, sevoflurane can be used in the intensive care unit via a specific heat and moister exchanger called the Anesthetic Conserving Device (AnaConDa®, SedanaMedical AB, Uppsala, Sweden) placed between the Y piece of the ventilatory circuit and the endotracheal tube. Sevoflurane is known to have ventilatory interesting effects such as bronchodilatation that can be useful in the treatment of severe asthma. These effects could be of interest in the intensive care ventilated patients. On the other hand, the AnaConDa® device could have negative influence on ventilatory mechanics caused by the increased dead space and the resistance to air flow. This negative effect with worsening of work of breathing (WOB) was demonstrated with classic heat and moister exchanger compared to heated humidifiers in pressure support ventilation (PSV). In this way, we would like to study the mechanical effects of the sevoflurane administered with the AnaConDa® compared to a classic management with a heated humidifier and sedation with intravenous remifentanil in PSV consecutive intensive care patients.

Interventions

DEVICEAnesthetic Conserving Device

* Ventilation in PSV with the Anesthetic Conserving Device with remifentanil * Ventilation in PSV with the Anesthetic Conserving Device with sevoflurane

Sponsors

University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults ICU patients who are no more in acute state, intubated and ventilated in pressure support ventilation with intravenous sedation by remifentanil, with light sedation (RASS -1 to -2).

Exclusion criteria

* Respiratory distress.

Design outcomes

Primary

MeasureTime frame
Work Of Breathing (WOB) measured during the last 5 minutes of the 20 minutes period of each treatmentduring the last 5 minutes of the 20 minutes period of each treatment

Secondary

MeasureTime frame
Intrinsic positive end expiratory pressure (PEEPi), occlusion pressure (P0,1), peak expiratory resistance, respiratory rate, tidal volume, minute ventilation, death space volume.in PSV consecutive intensive care patients

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026